BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.25 Stock BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.25
Add to a list
To use this feature you must be a member
Log inSign up

BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.25 Share Price

Warrant

DE000PC6MCZ3

Market Closed - Börse Stuttgart 11:59:27 14/06/2024 am IST
0.09 EUR -10.00% Intraday chart for BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.25
Current month+12.50%
1 month-30.77%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors BU
More news

Quotes 5-day view

Date Price Change
14/24/14 0.09 -10.00%
13/24/13 0.1 -9.09%
12/24/12 0.11 +10.00%
11/24/11 0.1 +11.11%
10/24/10 0.09 +12.50%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 11:59 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC6MCZ
ISINDE000PC6MCZ3
Date issued 14/03/2024
Strike 65 $
Maturity 19/12/2025 (552 Days)
Parity 10 : 1
Emission price 0.3 €
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 0.33 €
Lowest since issue 0.06 €
Delta0.15x
Omega 5.719
Premium60.37x
Gearing38.49x
Moneyness 0.6338
Difference Strike 23.8 $
Difference Strike %+36.62%
Spread 0.02 €
Spread %18.18%
Theoretical value 0.1000
Implied Volatility 31.62 %
Total Loss Probability 91.87 %
Intrinsic value 0.000000
Present value 0.1000
Break even 66.07 €
Theta-0x
Vega0.01x
Rho0.01x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant